Literature DB >> 24218312

Entecavir-associated myopathy: a case report and literature review.

Kai Yuan1, Wang Guochun, Zhenguo Huang, Bing Lin, Huiqiong Zhou, Xin Lu.   

Abstract

INTRODUCTION: Entecavir, a nucleoside analog (NA), is effective for treatment of chronic hepatitis B virus (HBV) infection.
METHODS: We report the case of a patient we encountered with entecavir-associated myopathy. We also performed a literature review of myopathies associated with nucleoside analogs.
RESULTS: A 44-year-old man presented with a 3-month history of myalgia and progressive weakness. He had HBV infection and had received entecavir antiviral treatment for 5 years. Laboratory tests showed that serum creatine kinase levels were significantly elevated. Muscle histopathology showed abundant T-lymphocyte infiltration of muscle fibers, and HBV surface antigen and HBV core antigen were not present in muscle fibers. Entecavir-associated myopathy was subsequently diagnosed. The patient's symptoms eventually resolved, and serum CK levels decreased rapidly after he stopped receiving entecavir treatments.
CONCLUSIONS: Patients who receive NA therapy should be closely monitored for myopathic side effects. Muscle Nerve 49:610-614, 2014.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  creatine kinase; entecavir; hepatitis B; myopathy; nucleoside analog

Mesh:

Substances:

Year:  2014        PMID: 24218312     DOI: 10.1002/mus.24118

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

Review 1.  Adverse effects of oral antiviral therapy in chronic hepatitis B.

Authors:  Bircan Kayaaslan; Rahmet Guner
Journal:  World J Hepatol       Date:  2017-02-18

2.  Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report.

Authors:  Xiao Lin; Aixin Song; Sujun Zheng; Xinyue Chen
Journal:  BMC Infect Dis       Date:  2022-02-24       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.